<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Gland Pharma Ltd. — News on 6ix</title>
<link>https://6ix.com/company/gland-pharma-limited</link>
<description>Latest news and press releases for Gland Pharma Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 15 May 2026 11:02:52 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/gland-pharma-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68364b6f78dffbe2df1534fb.webp</url>
<title>Gland Pharma Ltd.</title>
<link>https://6ix.com/company/gland-pharma-limited</link>
</image>
<item>
<title>Press Release May 15 2026</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-may-15-2026-23</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-may-15-2026-23</guid>
<pubDate>Fri, 15 May 2026 11:02:52 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Q4FY26 Audited Financial results".</description>
</item>
<item>
<title>Press Release Mar 04 2026</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-mar-04-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-mar-04-2026-5</guid>
<pubDate>Wed, 04 Mar 2026 16:04:41 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Gland Pharma Receives Tentative Approval for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC)".</description>
</item>
<item>
<title>Press Release Feb 06 2026</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-feb-06-2026-9</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-feb-06-2026-9</guid>
<pubDate>Fri, 06 Feb 2026 16:11:22 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Gland Pharma Receives Approval for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/ mL) Single-Dose Bags".</description>
</item>
<item>
<title>Press Release Jan 28 2026</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-jan-28-2026-14</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-jan-28-2026-14</guid>
<pubDate>Wed, 28 Jan 2026 22:23:08 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "UFR Q3FY26".</description>
</item>
<item>
<title>Press Release Jan 07 2026</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-jan-07-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-jan-07-2026-6</guid>
<pubDate>Wed, 07 Jan 2026 20:40:19 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated January 07, 2026, titled "Gland Pharma receives approval from the United States Food and Drug Administration (USFDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)".</description>
</item>
<item>
<title>Press Release Nov 03 2025</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-nov-03-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-nov-03-2025-11</guid>
<pubDate>Mon, 03 Nov 2025 21:51:34 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated November 03, 2025, titled "Press release on Q2FY26 Financial Results".</description>
</item>
<item>
<title>Press Release Aug 26 2025</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-aug-26-2025-4</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-aug-26-2025-4</guid>
<pubDate>Tue, 26 Aug 2025 15:56:10 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated August 26, 2025, titled "Gland Pharma receives approval from the United States Food and Drug Administration (USFDA) for Vasopressin 5% Dextrose Injection USP (RTU vial)".</description>
</item>
<item>
<title>Press Release Aug 12 2025</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-aug-12-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-aug-12-2025-11</guid>
<pubDate>Tue, 12 Aug 2025 16:56:36 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated August 12, 2025, titled "Gland Pharma Receives Approval for Norepinephrine Bitartrate in 5% DextroseInjection Bags".</description>
</item>
<item>
<title>Press Release Aug 05 2025</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-aug-05-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-aug-05-2025-10</guid>
<pubDate>Tue, 05 Aug 2025 20:42:39 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated August 05, 2025, titled "Q1Fy26 Results".</description>
</item>
<item>
<title>Press Release Jun 04 2025</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-jun-04-2025-6</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-jun-04-2025-6</guid>
<pubDate>Wed, 04 Jun 2025 12:16:35 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated Jun 04, 2025, titled "Gland Pharma receives approval from the United States Foodand Drug Administration (USFDA) for Angiotensin II Acetate Injection 2.5 mg/mL".</description>
</item>
<item>
<title>Press Release May 20 2025</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-may-20-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-may-20-2025-11</guid>
<pubDate>Tue, 20 May 2025 20:57:40 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated May 20, 2025, titled "Press Release on Q4 FY25 Results".</description>
</item>
<item>
<title>Press Release Apr 30 2025</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-apr-30-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-apr-30-2025-10</guid>
<pubDate>Wed, 30 Apr 2025 18:04:30 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Gland Pharma Receives Approval from USFDA for Latanoprostene Bunod Ophthalmic Solution".</description>
</item>
<item>
<title>Press Release Apr 03 2025</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-apr-03-2025-5</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-apr-03-2025-5</guid>
<pubDate>Thu, 03 Apr 2025 15:15:58 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated April 03, 2025, titled "Gland Pharma receives approval for Acetaminophen Injection".</description>
</item>
<item>
<title>Press Release Feb 03 2025</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-feb-03-2025-4</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-feb-03-2025-4</guid>
<pubDate>Mon, 03 Feb 2025 22:33:29 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated February 03, 2025, titled "Press Release on Q3FY25 Financial Results".</description>
</item>
<item>
<title>Press Release Dec 11 2024</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-dec-11-2024-5</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-dec-11-2024-5</guid>
<pubDate>Wed, 11 Dec 2024 23:14:30 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated December 11, 2024, titled "Gland Pharma receives approval for Phytonadione Injectable Emulsion".</description>
</item>
<item>
<title>Press Release Dec 03 2024</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-dec-03-2024-6</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-dec-03-2024-6</guid>
<pubDate>Tue, 03 Dec 2024 15:28:15 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated December 03, 2024, titled "Gland Pharma receives approval for Latanoprost Ophthalmic Solution".</description>
</item>
<item>
<title>Press Release Nov 04 2024</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-nov-04-2024-7</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-nov-04-2024-7</guid>
<pubDate>Mon, 04 Nov 2024 22:57:49 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated November 04, 2024, titled "Press Release on Q2FY25 Results".</description>
</item>
<item>
<title>Press Release Aug 06 2024</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-aug-06-2024-18</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-aug-06-2024-18</guid>
<pubDate>Tue, 06 Aug 2024 21:11:13 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated August 06, 2024, titled "Press Release on Q1 FY25 Results".</description>
</item>
<item>
<title>Press Release Jul 23 2024</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-jul-23-2024-5</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-jul-23-2024-5</guid>
<pubDate>Tue, 23 Jul 2024 18:53:22 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated July 23, 2024, titled "Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution ".</description>
</item>
<item>
<title>Press Release Jun 07 2024</title>
<link>https://6ix.com/company/gland-pharma-limited/news/press-release-jun-07-2024-3</link>
<guid isPermaLink="true">https://6ix.com/company/gland-pharma-limited/news/press-release-jun-07-2024-3</guid>
<pubDate>Fri, 07 Jun 2024 22:25:40 GMT</pubDate>
<description>Gland Pharma Limited has informed the Exchange regarding a press release dated Jun 07, 2024, titled "Srinivas Sadu appointed as Executive Chairman and CEO of Gland Pharma Limited".</description>
</item>
</channel>
</rss>